Patents by Inventor Walter C. Low

Walter C. Low has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11406697
    Abstract: In one embodiment, the present invention is a method of treating glioma and medulloblastoma brain tumors using the Zika virus and a tumor vaccine.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: August 9, 2022
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Walter C. Low, Maple Shiao, Andrew Crane, Christopher J. Sipe, Clairice Pearce, Joseph Voth, Nikolas Toman, Craig Bierle, Matthew Chrostek
  • Publication number: 20200345826
    Abstract: In one embodiment, the present invention is a method of treating glioma and medulloblastoma brain tumors using the Zika virus and a tumor vaccine.
    Type: Application
    Filed: March 4, 2020
    Publication date: November 5, 2020
    Inventors: Walter C. Low, Maple Shiao, Andrew Crane, Christopher J. Sipe, Clairice Pearce, Joseph Voth, Nikolas Toman, Craig Bierle, Matthew Chrostek
  • Patent number: 10610583
    Abstract: In one embodiment, the present invention is a method of treating glioma and medulloblastoma brain tumors using the Zika virus and a tumor vaccine.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: April 7, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: Walter C. Low, Maple Shaio, Andrew Crane, Christopher J. Sipe, Clairice Pearce, Joseph Voth, Nikolas Toman, Craig Bierle, Matthew Chrostek
  • Publication number: 20190060439
    Abstract: In one embodiment, the present invention is a method of treating glioma and medulloblastoma brain tumors using the Zika virus and a tumor vaccine.
    Type: Application
    Filed: August 29, 2018
    Publication date: February 28, 2019
    Inventors: Walter C. Low, Maple Shaio, Andrew Crane, Chris Sipe, Clairice Pearce, Joseph Voth, Nicolas Toman, Craig Bierle
  • Patent number: 10201715
    Abstract: An apparatus includes a substrate and a plurality of biological material stimulators positioned on the substrate. Each biological material stimulator forms a fluctuating magnetic field capable of inducing a current in biological material.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 12, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Jian-Ping Wang, Walter C. Low, Mahendra DC
  • Publication number: 20160303392
    Abstract: An apparatus includes a substrate and a plurality of biological material stimulators positioned on the substrate. Each biological material stimulator forms a fluctuating magnetic field capable of inducing a current in biological material.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Jian-Ping Wang, Walter C. Low, Mahendra DC
  • Publication number: 20080194531
    Abstract: The present invention provides methods for treating visual disorders. Exemplary visual disorders include macular degeneration, retinitis pigmentosa, glaucoma, and/or retinal degeneration.
    Type: Application
    Filed: February 8, 2006
    Publication date: August 14, 2008
    Inventors: Clifford J. Steer, Walter C. Low, Timothy W. Olson, Jeffrey H. Boatright, John M. Nickerson, Cecilia M.P. Rodrigues, Machelle T. Pardue
  • Publication number: 20080124366
    Abstract: The present invention is based on the finding that toll-like receptor (TLR) agonists affect immune responses in a subject. The compositions and methods of the present invention include administering to the subject a therapeutically effective amount of a tumor lysate or tumor lysis agent in conjunction with a therapeutically effective amount of a TLR agonist.
    Type: Application
    Filed: August 6, 2007
    Publication date: May 29, 2008
    Inventors: John R. Ohlfest, Walter C. Low, Wei Chen
  • Publication number: 20030105047
    Abstract: A method is disclosed for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance to the infusion site of the brain, the at least one substance capable of altering a nucleotide in a DNA sequence of a gene to convert a codon in a protein-coding region of the gene into a stop codon in the brain, whereby neurodegeneration in the brain is reduced. In a preferred embodiment, the at least one substance is a mutational vector, for example, a RNA/DNA chimeric mutational vector. The disclosed invention provides a method for treating neurodegenerative disorders such as Huntington's disease, spinocerebellar ataxia type 1, type 2, type 3, type 6, and/or type 7, spinobulbar muscular atrophy (Kennedy's disease), and/or dentatorubral-pallidoluysian atrophy (DRPLA).
    Type: Application
    Filed: April 26, 2002
    Publication date: June 5, 2003
    Applicant: Medtronic, Inc.
    Inventors: William F. Kaemmerer, Christopher D. Keene, Betsy J. Kren, Walter C. Low, Clifford J. Steer
  • Patent number: 6071891
    Abstract: A composition and method for inhibiting the growth and metastasis of breast tumors, including a tumor immunogen derived from breast tumor cells treated with an antisense oligonucleotide complementary to a gene or mRNA for the receptor for insulin-like growth factor type 1.
    Type: Grant
    Filed: November 22, 1996
    Date of Patent: June 6, 2000
    Assignee: Regents of the University of Minnesota
    Inventors: Walter C. Low, Margaret A. Wallenfriedman, Lan Chiang
  • Patent number: 5994320
    Abstract: The invention provides compositions and methods for treating primary brain cancer. The compositions include at least one antisense oligonucleotide that inhibits the proliferation of primary brain cancer cells. The antisense oligonucleotides are preferably complementary to and hybridize to a mRNA encoding c-myb. A method of the invention involves treating patients with primary brain cancer with a pharmaceutical composition including at least one antisense oligonucleotide in an amount effective to inhibit primary brain cell proliferation. The invention also provides probes and primers useful to identify primary brain cells having amplified and/or rearranged genes encoding c-myb.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: November 30, 1999
    Assignee: Regents of the University of Minnesota
    Inventors: Walter C. Low, Eric P. Flores, Walter A. Hall, Lan Chiang, John A. Conrad
  • Patent number: 5837231
    Abstract: A method for inhibiting the growth of brain tumors comprising peripheral administration of GM-CSF in combination with brain tumor antigen.
    Type: Grant
    Filed: June 27, 1996
    Date of Patent: November 17, 1998
    Assignee: Regents of the University of Minnesota
    Inventors: Walter C. Low, Margaret A. Wallenfriedman